Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

130 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Effect of adding gefitinib to neoadjuvant chemotherapy in estrogen receptor negative early breast cancer in a randomized phase II trial.
Bernsdorf M, Ingvar C, Jörgensen L, Tuxen MK, Jakobsen EH, Saetersdal A, Kimper-Karl ML, Kroman N, Balslev E, Ejlertsen B. Bernsdorf M, et al. Among authors: balslev e. Breast Cancer Res Treat. 2011 Apr;126(2):463-70. doi: 10.1007/s10549-011-1352-2. Epub 2011 Jan 15. Breast Cancer Res Treat. 2011. PMID: 21234672 Clinical Trial.
retrospective analysis of topoisomerase IIa amplifications and deletions as predictive markers in primary breast cancer patients randomly assigned to cyclophosphamide, methotrexate, and fluorouracil or cyclophosphamide, epirubicin, and fluorouracil: Danish Breast Cancer Cooperative Group.
Knoop AS, Knudsen H, Balslev E, Rasmussen BB, Overgaard J, Nielsen KV, Schonau A, Gunnarsdóttir K, Olsen KE, Mouridsen H, Ejlertsen B; Danish Breast Cancer Cooperative Group. Knoop AS, et al. Among authors: balslev e. J Clin Oncol. 2005 Oct 20;23(30):7483-90. doi: 10.1200/JCO.2005.11.007. J Clin Oncol. 2005. PMID: 16234514 Clinical Trial.
Lack of TIMP-1 tumour cell immunoreactivity predicts effect of adjuvant anthracycline-based chemotherapy in patients (n=647) with primary breast cancer. A Danish Breast Cancer Cooperative Group Study.
Willemoe GL, Hertel PB, Bartels A, Jensen MB, Balslev E, Rasmussen BB, Mouridsen H, Ejlertsen B, Brünner N. Willemoe GL, et al. Among authors: balslev e. Eur J Cancer. 2009 Sep;45(14):2528-36. doi: 10.1016/j.ejca.2009.05.029. Epub 2009 Jun 15. Eur J Cancer. 2009. PMID: 19535243 Clinical Trial.
Aberrations of ERBB2 and TOP2A genes in breast cancer.
Nielsen KV, Müller S, Møller S, Schønau A, Balslev E, Knoop AS, Ejlertsen B. Nielsen KV, et al. Among authors: balslev e. Mol Oncol. 2010 Apr;4(2):161-8. doi: 10.1016/j.molonc.2009.11.001. Epub 2009 Nov 18. Mol Oncol. 2010. PMID: 19945923 Free PMC article.
130 results